Animal studies indicated that carrimycin and monomeric isovalerylspiramycin I could significantly inhibit tumor volume, tumor histopathology, and the concentration of VEGF in two mouse models for HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.